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The Fas ligand (FasL)/Fas pathway is crucial for homeostasis of the immune system and peripheral
tolerance. Peripheral lymphocyte deletion involves FasL/Fas in at least two ways: coexpression of both Fas and
its ligand on T cells, leading to activation-induced cell death, and expression of FasL by nonlymphoid cells,
such as intestinal epithelial cells (IEC), that kill Fas-positive T cells. We demonstrate here that superantigen
Staphylococcus enterotoxin B (SEB) induced a dramatic upregulation of FasL, TRAIL, and TNF mRNA
expression and function in IEC from BALB/c and C57BL/6 mice. Using adoptive transfer in which CD4! T cells
from OT-2 T-cell receptor transgenic mice were transferred into recipients, we observed an induction in IEC
of FasL, TRAIL, and TNF mRNA after administration of antigen. Specific Egr-binding sites have been
identified in the 5! promoter region of the FasL gene, and Egr-1, Egr-2, and Egr-3 mRNA in IEC from mice
treated with SEB and from transgenic OT-2 mice after administration of antigen was upregulated. Overex-
pression of Egr-2 and Egr-3 induced endogenous ligand upregulation that was inhibited by overexpression of
Egr-specific inhibitor Nab1. These results support a role for Egr family members in nonlymphoid expression
of FasL, TRAIL, and TNF.
Apoptosis-inducing members of the tumor necrosis factor
(TNF) family, the so-called death ligands, include TNF, FasL,
and TNF-related apoptosis-inducing ligand (TRAIL). These
ligands and their receptors play pivotal roles in the regulation
of the immune system, especially via induction of apoptosis in
activated lymphocytes. In particular, they have been implicated
in the process of activation-induced cell death (AICD) in T
lymphocytes, in which repeated antigen stimulation of T cells
induces apoptosis through the induction of death ligand ex-
pression and sensitization to death receptor-induced apoptosis
(3, 6, 13, 44). Death ligand-mediated AICD is at least one
mechanism for peripheral deletion, the process whereby ex-
panding clones of activated T cells subsequently decrease in
number (31).
The roles for death ligands in immune regulation include
expression of death ligands in nonlymphoid tissues. Immune
privilege in the anterior chamber of the eye requires functional
FasL expression in this organ, which induces apoptosis in in-
filtrating lymphocytes (9). Similarly, functional FasL expres-
sion on the cornea contributes to graft acceptance in an animal
model of cornea transplant (42). More recent studies have
shown that epithelial cells of the eye express, in addition to
FasL, TRAIL (21) and TNF (8), which may also contribute to
immune privilege.
Other nonlymphoid tissues express FasL only during im-
mune responses involving extensive T-cell activation, and this
is also likely to contribute to peripheral deletion (36). Such
tissues include the lung, liver, and small intestine. More re-
cently, we demonstrated that expression of FasL on intestinal
epithelial cells (IEC) is induced by TNF in response to antigen
(35). TNF-induced FasL expression in IEC was found to depend
on activation of NF-"B and its effect on the FasL promoter.
Cyclosporine has been shown to interfere with AICD (41),
suggesting that cyclosporine-sensitive transcription factors may
be involved. Indeed, several studies have demonstrated roles
for the cyclosporine-sensitive nuclear factor of activated T cells
(NFAT) transcription factor and for early-growth-response
transcription factors, mainly Egr-2 and Egr-3, in T-cell expres-
sion of the FasL gene following T-cell receptor (TCR) ligation
(7, 38). NFAT is a family of transcription factors that are
present in the cytoplasm in a phosphorylated form. After de-
phosphorylation mediated by the phosphatase calcineurin,
these factors are rapidly translocated into the nucleus, where
they activate different genes, including those encoding cell
surface receptors, signaling molecules, and cytokines. Double
knockout mice lacking both NFATp and NFAT4 exhibit im-
paired induction of FasL and a lymphoproliferative disorder,
suggesting a key role for these transcription factors in FasL
transcription (37).
While several studies postulate that NFAT may be a direct
regulator of FasL (19, 20, 23), it has also been demonstrated
that the cyclosporine-inhibitable Egr-2 and Egr-3 transcription
factors are potent regulators of FasL expression (29, 30). This
family is composed of four members: Egr-1 (NGFI-A, krox24,
zif268), Egr-2 (krox20), Egr-3 (PILOT), and Egr-4 (NGFI-C).
All of these members share a highly conserved DNA-binding
domain composed of three zinc finger motifs that bind and
transactivate transcription from the consensus sequence GCG
GGGGCG (33). Similar to some other transcription factors,
Egr members associate with corepressor proteins Nab1 and
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Nab2, which can modulate transcription of Egr-dependent
genes. These factors bind to Egr-1, Egr-2, and Egr-3 by direct
protein-protein interactions with a conserved R1 domain, in-
hibiting the transactivating potential of these transcription fac-
tors (32).
Here, we extend our observations on FasL expression in IEC
to other death ligands and transcription factors. We report that
Egr-1, Egr-2, and Egr-3 mRNA is upregulated in IEC from
BALB/c and C57BL/6 mice challenged with superantigen
Staphylococcus enterotoxin B (SEB) and from transgenic OT-2
mice after administration of antigen. Overexpression of Egr-2,
Egr-3, or TNF in IEC induces endogenous FasL, TRAIL, and
TNF upregulation, whereas Nab1 coexpression completely
abolishes these effects. These results support a role for Egr
family members in nonlymphoid expression of FasL, TRAIL,
and TNF.
MATERIALS AND METHODS
Cell lines and animals. All animals were bred in house or purchased from
Jackson Laboratories (Bar Harbor, Maine) and housed under pathogen-free
conditions at the La Jolla Institute for Allergy and Immunology. All cell lines
were obtained from the American Type Culture Collection (Manassas, Va.),
including L1210 and HT29 cells, and grown in suspension culture medium RPMI
1640. Primary IEC were isolated from small intestines according to the proce-
dure previously described (22) and cultured in Dulbecco’s modified Eagle’s
medium. Each medium was supplemented with 10% (vol/vol) heat-inactivated
fetal bovine serum, 2 mM L-glutamine, 100 U of penicillin/ml, and 100 #g of
streptomycin/ml, and the cells were grown in 5% CO2 at 37°C.
Adoptive transfer and antigenic stimulation. CD4! lymphocyte subsets were
enriched as previously described (36), and lymphocytes (5 $ 106 to 10 $ 106)
were introduced into the tail veins of recipient animals. Superantigen SEB (75 to
100 #g/mouse; Sigma) was injected intraperitoneally (i.p.) into BALB/c mice.
OT-2 TCR transgenic animals and recipients of OT-2 lymphocytes were treated
subcutaneously (s.c.) with the ovalbumin (OVA) peptide consisting of amino
acids 323 to 339 (OVA 323-339 peptide) at 300 #g per mouse. The OVA 323-329
peptide introduced s.c. was delivered in complete Freund’s adjuvant (15).
Functional assay for FasL and TRAIL expression. FasL and TRAIL activities
were detected by the ability of IEC to induce DNA fragmentation in Fas-positive
and TRAIL receptor 2 (TRAIL-R2)-positive target cells (3, 21). Briefly, parental
L1210 and L1210-Fas, both containing TRAIL-R2, were labeled with 5 #Ci of
[3H]thymidine/ml for 4 h (39). After incubation, cells were rinsed twice with
Hanks balanced salt solution (HBSS) to remove unincorporated thymidine.
Target cells were then incubated in complete medium with dissociated epithelial
cells from the small intestines of control or treated mice in 96-well plates in the
presence or absence of Fas-Fc and/or TRAIL-R2–Fc (R&D Systems, Minneap-
olis, Minn.). After 18 h, cells were harvested with a multiautomated system
harvester, and DNA was counted in a beta counter. DNA fragmentation was
determined as previously described (2).
Real-time reverse transcription-PCR (RT-PCR). Total RNA was isolated
from primary IEC with Trizol (Gibco BRL, Rockville, Md.) according to the
manufacturer’s instructions. RNA was reverse transcribed by Moloney murine
leukemia virus reverse transcriptase (Gibco BRL) with random hexamers (Gibco
BRL). For FasL gene expression, primers were located in separate exons in
genomic DNA in order to eliminate the possibility of genomic DNA contami-
nation. Sequence-specific primers for murine FasL, TNF, %-actin, 18S, and lu-
ciferase were previously described (35). Specific forward and reverse primers
were, respectively, as follows: murine TRAIL, 5&-CCTCTCGGAAAGGGCAT
TC-3& and 5&-TCCTGCTCGATGACCAGCT-3&; Egr-1, 5&-GGCGATGGTGG
AGACGAGT-3& and 5&-CGGCCAGTATAGGTGATGGG-3&; Egr-2, 5&-TCTC
CGTGCCAGAGAGATCC-3& and 5&-GAGGACAGGGAAACGGCTTT-3&;
Egr-3, 5&-CACTGGAGACCATCAAGGCC-3& and 5&-GGGCAGGCTGCCGA
A-3&; TRAIL-R2, 5&-TGCTGCTCAAGTGGCGC-3& and 5&-GGCATCCAGCA
GATGGTTG-3&; human FasL, 5&-CAGTCCACCCCCTGAAAAAAAA-3& and
5&-CCAGAGGCATGGACCTTGAG-3&; 18S, 5&-ACATCCAAGGAAGGCAG-
CAG-3& and 5&-TCGTCACTACCTCCCCGG-3&; LacZ, 5&-AATGGCTTTCGC
TACCTGGA-3& and 5&-CCATCGCGTGGGCGTA-3&; green fluorescent pro-
tein (GFP), 5&-TGGCCCTGTCCTTTTACCAG-3& and 5&-TTTTCGTTGGGA
TCTTTCGAA-3&; Renilla, 5&-AATTTGCAGCATATCTTGAACCATT-3& and
5&-GGATTTCACGAGGCCATGAT-3&. Real-time PCR was performed with
AmpliTaq Gold polymerase in a PE Biosystems 5700 thermocycler using the
SyBr Green detection protocol as outlined by the manufacturer. Briefly, 12 ng of
total cDNA, 50 nM (each) primer, and 1$ SyBr Green mixture were used in a
total volume of 25 #l.
Plasmid constructs and retrovirus gene transfer. Murine Egr-2, Egr-3, and
Nab1 cDNAs were amplified by RT-PCR from total RNA using the Egr-2
forward primer (5&-ATGAACGGAGTGGCGGGAGATGGC-3&), Egr-2 re-
verse primer (5&-TCACGGTGTCCTGGTTCGAGAGGT-3&), Egr-3 forward
primer (5&-ATGACCGGCAAACTCGCCGAG-3&), Egr-3 reverse primer (5&-T
CAGGCGCAGGTGGTGACCAC-3&), Nab1 forward primer (5&-ATGGCCAC
AGCCTTACCTAGGACCCTG-3&), and Nab1 reverse primer (5&-CTATCTTG
AGTCTTCAGGCTCTG-3&) at the respective ATG start and stop codons. All
amplified fragments were cloned directly into the pcDNA3.1V5-TOPO vector
(Invitrogen, Carlsbad, Calif.) and sequenced according to the manufacturer’s
instructions.
The hemagglutinin-tagged Egr-3 product was generated by PCR using the
Egr-3 forward primer containing an EcoRI restriction site (5&-TATAGAATTC
ATGACCGGCAAACTCGCCG-3&) and the Egr-3 reverse primer containing a
NotI restriction site (5&-TATAGCGGCCGCTTATGCATAATCTGGTACATC
GTATGGATAGGCGCAGGTGGTGACCACAGGGGC-3&). The PCR prod-
uct was digested with EcoRI and NotI and cloned into the retroviral pMX-IRES-
GFP vector, digested with EcoRI and NotI. Retrovirus production, HT29 cell
infection, and sorting were conducted as previously described (5).
Human FasL promoter constructs were generated by PCR. The bp '300 and
'240 regions were cloned with the 5&-CCCAAGCTTCGGCTGTTATCAGAA
AATTGTGGG-3& and the 5&-CCCAAGCTTCTTCTCAGCTTCAGCTGCAA
AGCG-3& sense primers together with the 5&-ACGCGTCGACCATGGCAGC
TGGTGAGTCAGGCCAGC-3& antisense primer. Egr and NFAT with mutations
in the bp '300 region were generated by PCR using the 5&-CCCAAGCTTCG
GCTGTTATCAGAAAATTTTAAACGGAAACTTCC-3& and the 5&-CCCAA
GCTTCGGCTGTTATCAGAAAATTGTGGGCGTCCCGATCCAGG-3& sense
primers, respectively, and Egr with mutations in the bp '240 region was generated
by PCR using the 5&-CCCAAGCTTCTTCTCAGCTTCAGCTGCAAAGCTCTA
AATGTTTCT-3& sense primer. All amplified fragments were cloned directly into
the pGLOW vector (Invitrogen) and sequenced according to the manufacturer’s
instructions.
Transient-transfection and reporter assays. In transient-expression experi-
ments, all transfections were performed with Superfect (Qiagen, Valencia, Calif.)
according to the manufacturer’s instructions and 0.5 #g of each vector. Trans-
fected IEC, HT29, and Egr3-HT29 cells were incubated for 18 h at 37°C before
analysis by real-time PCR. Due to the low efficiency of transient transfection,
TNF, Egr2, Egr3, and Nab1 overexpression was checked by real-time PCR. The
antagonist anti-TNF receptor type 1 (TNFR1) antibody (clone 55R-170) was
used at a concentration of 2 #g/ml. GFP mRNA was analyzed by real-time
RT-PCR, and transfection efficiencies were measured by analysis of Renilla or
luciferase reporter mRNA expression.
Protein extraction and Western blot analysis. The antibodies used in this study
included anti-TRAIL, anti-FasL (Santa Cruz Biotechnology, Santa Cruz, Calif.),
anti-TNF (a gift from Carl F. Ware), and antiactin (ICN, Aurora, Ohio). For
protein extraction, cells were washed twice in phosphate-buffered saline (PBS),
lysed in buffer containing 150 mM NaCl, 50 mM pH 8.0 Tris-HCl, 0.1% Na-
sodium dodecyl sulfate (SDS), and 0.5% Na deoxycholate in the presence of
protease inhibitors for 30 min at 4°C and then centrifuged (20 min; 15,000 $ g)
and supernatants were collected. For Western blots, after SDS-polyacrylamide
gel electrophoresis and electrotransfer to nitrocellulose membranes (Amersham
Biosciences), the membranes were incubated for at least 1 h with 5% nonfat milk
in TPBS (0.1% Tween 20, 1$ PBS) and for 2 h at room temperature with
primary antibodies. Horseradish peroxidase-conjugated goat anti-rabbit, anti-
hamster, or anti-mouse secondary antibodies were then added for 30 to 60 min,
and proteins were revealed by enhanced chemiluminescence reagent (Pierce,
Rockford, Ill.) and autoradiography.
RESULTS
FasL, TRAIL, and TNF mRNA are upregulated in IEC after
SEB injection. We have previously established that the super-
antigen SEB induces a dramatic upregulation of FasL expres-
sion and function in nonlymphoid cells of the liver and small
intestine (2). Using real-time RT-PCR, we studied the expres-
sion of other death ligands of the TNF family in IEC from
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BALB/c and C57BL/6 mice injected with PBS or SEB. Inter-
estingly, we observed a dramatic upregulation of TRAIL and
TNF mRNA in these cells 3 days after SEB injection (Fig. 1A
and B). In keeping with our previous observations, an increase
in FasL protein levels in response to superantigen-induced
activation of peripheral lymphocytes and an increase in
TRAIL and TNF protein levels were also observed (Fig. 1C).
OT-2 transfer induces FasL, TRAIL, and TNF mRNA up-
regulation. hFlp-lacZ transgenic mice express a LacZ con-
struct under the control of the proximal promoter of the hu-
man FasL gene (36), and antigenic challenge of these mice
resulted in increased expression of nonlymphoid FasL as well
as LacZ in the epithelium of the small intestine (36). To study
the expression of the different death ligands in IEC, we em-
ployed an adoptive-transfer approach in which CD4! T cells
from OT-2 TCR (OVA-plus-I-Ab-responsive) transgenic mice
were transferred into transgenic hFlp-lacZ recipient mice (OT-
23hFlp-lacZ mice). OT-23hFlp-lacZ recipients were chal-
lenged with the OVA peptide; 3 days later IEC were isolated
and RNA was assessed by real-time RT-PCR for endogenous
FasL, LacZ, TRAIL, and TNF expression. In keeping with our
previous findings, we observed that induction of expression of
LacZ mRNA correlated with expression of FasL mRNA after
administration of antigen (Fig. 2A). We also observed a sig-
nificant induction of TRAIL and TNF mRNAs, demonstrating
that activated lymphocytes induced accumulation of these dif-
ferent ligands at the mRNA level. A similar effect was ob-
served when hFlp-lacZ $ OT-2 double-transgenic animals
were immunized directly with OVA (Fig. 2B).
FasL, TRAIL, and TNF induction in IEC is TNF dependent.
We recently reported that FasL expression in IEC is induced in
activated T cells through a TNF-dependent mechanism (35).
To determine if TRAIL and TNF mRNA expression in the IEC
is also induced by TNF production, we injected TNF into mice
and examined ligand expression in the epithelium of the small
FIG. 1. IEC FasL, TRAIL, and TNF are induced in response to
superantigen. BALB/c (A) and C57BL/6 (B) mice were injected i.p.
with superantigen SEB (75 to 100 #g), and after 3 days IEC total
mRNA was isolated and assessed by real-time RT-PCR for TRAIL and
TNF mRNA expression. Independent data from two SEB-treated mice
are shown for each strain. Absolute mRNA values were determined,
normalized to %-actin, and reported as arbitrary units. (C) FasL,
TRAIL, and TNF protein levels were also assessed by Western blot-
ting. Independent results from three SEB-treated mice are shown.
FIG. 2. OT-2 transfer into hFlp-lacZ transgenic mice and antigen
stimulation in OT-2 $ hFlp-lacZ double-transgenic mice simulta-
neously induce FasL, TRAIL, and TNF upregulation. CD4! T cells
from OT-2 TCR transgenic mice were transferred into C57BL/6 re-
cipients. OT-23hFlp-lacZ recipients (A) and OT-2 $ hFlp-lacZ dou-
ble-transgenic (B) mice were challenged with OVA 323-339, and IEC
were isolated. The OVA peptide introduced s.c. was delivered in com-
plete Freund’s adjuvant. Total mRNA was isolated and assessed by
real-time RT-PCR for FasL, LacZ, TRAIL, and TNF mRNA expres-
sion. Absolute mRNA values were determined, normalized to %-actin,
and reported as arbitrary units.
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intestine. Injection of TNF (2 #g/mouse) resulted in a signif-
icant increase in TRAIL and TNF expression in IEC in vivo
(Fig. 3A). We then asked if TNF is necessary for upregulation
of TRAIL in IEC as it is for upregulation of FasL. To address
this question, wild-type and TNF'/' mice were injected with
SEB and 3 days later IEC mRNA was isolated and assayed by
real-time RT-PCR for TRAIL mRNA expression. We ob-
served a significant increase of TRAIL mRNA expression in
wild-type mice after SEB injection, whereas little TRAIL
mRNA was seen in TNF'/' mice (Fig. 3B). We have previ-
ously shown that IEC constitutively express TNFR1 (p55) (35)
and not TNFR2 (data not shown). To confirm that the ob-
served effect is dependent on TNFR1, wild-type and TNFR1'/'
mice were injected with SEB. Three days later total IEC
mRNA was isolated, and TRAIL and TNF mRNA expression
was assessed by real-time RT-PCR (Fig. 3C). Levels of TRAIL
and TNF mRNA expression in wild-type IEC were significantly
increased after SEB injection, whereas no upregulation was
seen for TRAIL and TNF in IEC from TNFR1'/' mice (Fig.
3C). Taken together, these results suggest that TNF is involved
in TRAIL expression following exposure to antigen.
IEC express functional FasL and TRAIL. FasL present in
nonlymphoid tissue has been shown to delete reactive lympho-
cytes during viral infection and after exposure to SEB or an
OVA peptide (2, 9, 36). To evaluate the function of nonlym-
phoid FasL and TRAIL, we isolated IEC from SEB-treated
and untreated animals and tested their ability to kill Fas!
target cells. As shown in Fig. 4, IEC from SEB-treated mice
killed targets bearing the Fas receptor (L1210-Fas), confirming
our previous observation (Fig. 4A). Because L1210-Fas also
expresses the TRAIL-R2 (Fig. 4B, inset), we used these cells to
examine the function of TRAIL by culturing the IEC and
target cells in the presence of Fas-Fc or TRAIL-R2–Fc. The
apoptosis induced by IEC in L1210-Fas cells was partially in-
hibited when Fas-Fc or TRAIL-R2–Fc was included in the
culture (Fig. 4B). We also observed a greater protection when
both Fas-Fc and TRAIL-R2–Fc were added together to the
culture in which IEC and targets were at a higher ratio (10:1),
suggesting a possible cooperation between these two ligands in
killing. However, the addition of both Fas-Fc and TRAIL-
R2–Fc did not completely inhibit cell death, and therefore it is
possible that other factors are also involved.
To further evaluate the function of nonlymphoid TRAIL, we
isolated IEC from SEB-treated C57BL/6-gld animals and
tested their ability to kill TRAIL-R2! target cells (L1210). IEC
from SEB-treated C57BL/6 animals induced apoptosis in
L1210 cells, and this apoptosis was partially inhibited when
TRAIL-R2–Fc was included in the culture (Fig. 4C). IEC from
SEB-treated C57BL/6-gld animals induced less apoptosis in
L1210 cells, presumably due to nonfunctional FasL, but the
observed death was almost completely inhibited when TRAIL-
R2–Fc was included in the culture (Fig. 4C). Again, the addi-
tion of TRAIL-R2–Fc did not completely inhibit cell death in
the higher-ratio (10:1) culture, suggesting that other factors
could be involved. Thus, the FasL and the TRAIL induced on
IEC by in vivo administration of SEB are biologically active.
Egr transcription factors are upregulated in IEC after SEB
and OVA injection. The Egr-1 transcription factor has been
shown to be involved in TNF expression, while Egr-2 or Egr-3
expression can induce FasL transcription in nonlymphoid cells
(17, 30). These observations suggest a possible role for Egr
transcription factors in FasL and TNF expression and perhaps
TRAIL expression. Egr family members are zinc finger pro-
teins that are rapidly induced in diverse cell types following cell
activation by different stimuli. Egr-1 mRNA is known to be
constitutively expressed in many tissues, whereas Egr-2 and
Egr-3 mRNA is not found in unactivated tissues (34), arguing
in favor of de novo synthesis mechanisms. Using real-time
RT-PCR, we studied endogenous Egr-1, Egr-2, and Egr-3 gene
expression in IEC from BALB/c, C57BL/6, B6129SF2 wild-
type, TNF'/', and TNFR1'/'mice injected with PBS or SEB.
We observed that Egr-1 mRNA is the major Egr mRNA ex-
pressed in these cells, while Egr-2 and Egr-3 mRNA is ex-
pressed at lower levels (Fig. 5). Constitutive Egr-2 and Egr-3
FIG. 3. Induction of nonlymphoid TRAIL and TNF mRNA is de-
pendent on TNF. (A) BALB/c mice were injected with TNF (2 #g),
and IEC were harvested 12 h later and analyzed for TRAIL and TNF
mRNA expression. Absolute mRNA values were determined, normal-
ized to 18S RNA, and reported as arbitrary units. Data from three
TNF-treated mice are shown. (B) B6129SF2 and TNF'/' mice were
injected with SEB. IEC were isolated 3 days after SEB administration
and analyzed for TRAIL mRNA expression. Absolute mRNA values
were determined, normalized to %-actin, and reported as arbitrary
units. (C) C57BL/6 and TNFR1'/' mice were injected with SEB. IEC
were isolated 3 days after SEB administration and analyzed for TRAIL
and TNF mRNA expression. Absolute mRNA values were deter-
mined, normalized to %-actin, and reported as arbitrary units.
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mRNA expression in some tissues is not consistent with pre-
vious observations (34) but can be explained by the fact that
real-time PCR is more sensitive than Northern analysis or
conventional RT-PCR.
In addition, we observed a dramatic upregulation of Egr-1,
Egr-2, and Egr-3 mRNA in wild-type IEC 3 days after SEB
injection (Fig. 5A). The kinetics of appearance of FasL,
TRAIL, and TNF mRNA in these cells after SEB injection
correlated with Egr expression (Fig. 1A and B). Egr-1, Egr-2,
and Egr-3 mRNA was also induced in IEC from hFlp-lacZ $
OT-2 double-transgenic mice after direct immunization with
OVA (Fig. 5B). To determine if Egr mRNA expression in IEC
was dependent on TNF, wild-type and TNF'/' mice were
injected with SEB and 3 days later IEC mRNA was isolated
and Egr expression was assessed by real-time RT-PCR (Fig.
6A). Egr-1 and Egr-3 mRNA expression in wild-type IEC was
significantly increased after SEB injection, whereas no upregu-
lation was seen for Egr-1, Egr-2, or Egr-3 in IEC from TNF'/'
mice (Fig. 6A).
We have shown that IEC express TNFR1 (35). To confirm
that the observed effect is dependent on TNFR1, wild-type and
TNFR1'/' mice were injected with SEB and 3 days later IEC
FIG. 4. Epithelial cells from the small intestines of SEB-treated mice have functional FasL and TRAIL. BALB/c mice were challenged in vivo
with PBS or SEB, and IEC were prepared. (A) IEC were cocultured with [3H]thymidine (TdR)-labeled L1210 or L1210-Fas target cells for 18 h
at the ratios indicated on the x axes. Induction of apoptosis in the targets was assessed as the percentage of specific DNA fragmentation. (B) The
contribution of FasL and TRAIL to the killing of L1210-Fas targets expressing TRAIL-R2, as assessed by real-time RT-PCR (inset), was studied
by inclusion of 5 mg of Fas-Fc and/or TRAIL-R2–Fc/ml. Induction of apoptosis in the L1210-Fas targets at the indicated ratios was assessed as
the percentage of specific DNA fragmentation. (C) C57BL/6 and C57BL/6-gld mice were challenged in vivo with SEB, and IEC were prepared.
The IEC were cocultured with [3H]TdR-labeled L1210 target cells for 18 h at the indicated ratios. The contribution of TRAIL to the killing of
L1210 targets was studied by inclusion of 5 mg of TRAIL-R2–Fc/ml. Induction of apoptosis in the L1210 targets at the indicated ratios was assessed
as the percentage of specific DNA fragmentation.
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mRNA was isolated and Egr expression was assessed by real-
time RT-PCR (Fig. 6B). Egr-2 and Egr-3 mRNA expression in
wild-type IEC was significantly increased after SEB injection,
whereas no upregulation was seen for Egr-1, Egr-2, or Egr-3 in
IEC from TNFR1'/' mice (Fig. 6B).
Egr-2 and Egr-3 transcription factors induce endogenous
FasL, TRAIL, and TNF upregulation in IEC. Egr family tran-
scription factors contain no known dimerization domains and
are known to bind to DNA and activate transcription as mono-
mers (32). Since Egr-1 did not appear to have a major role in
activation-induced upregulation of FasL transcription (30), we
studied endogenous ligand expression after Egr-2 or Egr-3
overexpression in primary IEC. Egr-2 or Egr-3 overexpression
was sufficient to induce endogenous FasL mRNA accumula-
tion in both cell types (Fig. 7). Interestingly, we also observed
an increase in endogenous TRAIL and TNF mRNA after Egr-2
or Egr-3 overexpression in primary IEC (Fig. 7).
Recently, a novel family of corepressors, named Nab, that
inhibits the transcriptional activity of the Egr family of zinc
finger transcription factors was identified (43). To determine if
endogenous FasL, TRAIL, and TNF mRNA expression is Egr
dependent, murine Nab1 was cloned and coexpressed with
Egr-2 or Egr-3. As expected, Nab1 expression inhibited Egr-
induced FasL, TRAIL, and TNF upregulation in primary IEC
(Fig. 7). To further analyze the effects of TNF and Egr mem-
FIG. 5. IEC Egr-1, -2, and -3 mRNA is induced in response to
superantigen and after antigen stimulation in OT-2 $ hFlp-lacZ dou-
ble-transgenic mice. BALB/c and C57BL/6 (A) and OT-2 $ hFlp-lacZ
double-transgenic (B) mice were injected i.p. with superantigen SEB
(75 to 100 #g) (A) or challenged with OVA (B), and after 3 days IEC
total mRNA was isolated and assessed by real-time RT-PCR for Egr-1,
Egr-2, and Egr-3 mRNA expression. Absolute mRNA values were
determined, normalized to %-actin, and reported as arbitrary units.
FIG. 6. IEC Egr-1, -2, and -3 mRNA expression is dependent on
TNF. B6129SF2 and TNF'/' (A) and C57BL/6 and TNFR1'/'
(B) mice were injected i.p. with superantigen SEB (75 to 100 #g), and
after 3 days IEC total mRNA was isolated and assessed by real-time
RT-PCR for Egr-1, Egr-2, and Egr-3 mRNA expression. Absolute
mRNA values were determined, normalized to %-actin, and reported
as arbitrary units.
FIG. 7. Transient overexpression of Egr-2 and Egr-3 induces en-
dogenous FasL, TRAIL, and TNF mRNA upregulation in primary
IEC. Primary IEC prepared from BALB/c mice were transfected with
different constructs expressing murine Egr-2, Egr-3, and/or Nab1.
Twenty hours later total mRNA isolated from transfected IEC was
analyzed for endogenous FasL, TRAIL, and TNF mRNA expression.
Absolute mRNA values were determined, normalized to 18S RNA,
and reported as arbitrary units.
VOL. 23, 2003 TNF LIGAND FAMILY EXPRESSION BY Egr MEMBERS 7643






bers on IEC, we expressed TNF in primary IEC by transient
transfection and assayed the effects on FasL and TRAIL
mRNA levels (Fig. 8). Primary IEC were transfected with
TNF-pcDNA in the presence or absence of an anti-TNFR1
antagonistic antibody, and 20 h later RNA was analyzed by
real-time RT-PCR. As we have previously shown (35), there
was a significant increase in FasL mRNA levels in TNF-trans-
fected IEC, and we also observed an increase in TRAILmRNA
(Fig. 8). The TNF-dependent effects on FasL and TRAIL ex-
pression were reduced to background levels when an anti-
TNFR1 antagonistic antibody was added to the medium (Fig.
8). We then examined the effect of Nab1 expression in the cells
expressing TNF (note that the expression of TNF allowed us to
examine the effects of Nab1 coexpression on endogenous li-
gand expression in the same cells). As shown in Fig. 8, the
expression of the Egr-specific inhibitor Nab1 inhibited TNF-
induced FasL and TRAIL upregulation. These results suggest
that TNF production induces Egr-dependent expression of
FasL and TRAIL in IEC.
To identify DNA elements that control the regulation of
FasL transcription, known regions of the human FasL gene 5&
of the translation start site containing Egr-binding sites were
used to drive the expression of a GFP reporter in primary IEC
(Fig. 9). Due to the difficulty in transfecting primary cells with
high efficiency to study reporter gene expression by conven-
tional assays, we developed an assay to study reporter expres-
sion at the mRNA level by real-time RT-PCR. In transient
transfections with the indicated GFP reporter constructs, ex-
pression of Egr-2 led to a weak induction of the bp '300
human FasL promoter reporter while Egr-3 induced strong
transcription (Fig. 9A and B). Surprisingly, truncation of the
FasL promoter to nucleotide '240, deleting putative overlap-
ping NFAT and Egr sites, did not inhibit the transcriptional
activity induced by Egr-2 but eliminated the response to Egr-3,
indicating that Egr-3 binds only the putative overlapping
NFAT and Egr sites. To determine if these sites are required
for FasL induction in IEC, we tested FasL promoter activity
using promoter-GFP constructs with specific mutations in the
binding sites for these transcription factors. Mutations within
the Egr or NFAT sites completely abolished the activity of the
bp '300 construct upon Egr-3 overexpression, suggesting that
mutation in the NFAT site affects Egr-3 binding to its own site
(Fig. 9). The role of Egr-3 at the putative overlapping NFAT
and Egr sites in the FasL promoter was confirmed by using
HT29 cells overexpressing Egr-3 (Fig. 9C). In this experiment,
FIG. 8. Endogenous FasL and TRAIL mRNA upregulation in-
duced by TNF is inhibited by Nab1 overexpression in IEC. Primary
IEC prepared from BALB/c mice were transfected with different con-
structs expressing murine Egr-2 or Egr-3 either alone, in the presence
of a neutralizing TNFR1 antibody (Ab), or with Nab1. Twenty hours
later total mRNA was isolated from transfected IEC and analyzed for
FasL (A) and TRAIL (B) mRNA by real-time RT-PCR. Absolute
mRNA values were determined, normalized to 18S RNA, and re-
ported as arbitrary units.
FIG. 9. Expression of exogenous Egr-3 and Egr-2 protein is suffi-
cient to induce FasL-responsive-element-dependent transcription in
nonlymphoid cells. Primary IEC prepared from BALB/c mouse cells
were cotransfected with different constructs expressing murine Egr-2
(A) or Egr-3 (B) with the indicated GFP reporter plasmids with sche-
matic Egr (blue boxes) and NFAT (purple boxes) sites. X, mutated Egr
and NFAT sites. GFP mRNA was analyzed by real-time RT-PCR and
normalized to luciferase mRNA expression as an efficiency control.
(C) HT29 cells were infected with either an internal ribosomal entry
site (IRES)-GFP control retrovirus or an IRES-GFP retrovirus ex-
pressing wild-type murine Egr-3. Stably infected cells were sorted by
fluorescence-activated cell sorter to(95% GFP-expressing cells. Egr-3
mRNA expression was assessed by real-time RT-PCR. (Inset) HT29
and Egr3-HT29 cells were cotransfected with the indicated GFP re-
porter plasmids and a Renilla vector as a control. GFP mRNA was
analyzed by real-time RT-PCR and normalized to Renilla mRNA.
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this site was again required for Egr-3-induced FasL promoter
activity.
DISCUSSION
In this paper, we have shown that IEC express not only FasL
but also TRAIL and TNF in response to superantigen- or
peptide-induced activation of peripheral lymphocytes. In keep-
ing with our previous observations, we found that the expres-
sion of these different ligands in IEC depends on TNF (35).
Our results suggest a model in which TNF, produced by lym-
phoid cells after activation by superantigen or peptide (16),
induces Egr-dependent expression of FasL, TRAIL, and TNF
in IEC through TNFR1. Biologically active FasL and TRAIL
expressed in the small intestine may then kill infiltrating Fas!
and TRAIL-R2! T cells (Fig. 10).
One function of the TNF ligand family is the induction of
apoptosis. Constitutive expression of TRAIL mRNA has been
reported in most normal tissues and cell types (10). TRAIL is
not expressed on freshly isolated T cells; however, both TRAIL
and the TRAIL receptor are upregulated upon T-cell activa-
tion (12, 25, 40). For example, CD4! V)24NKT cells express
TRAIL only when the cells are activated by )-galactosylcer-
amide-pulsed dendritic cells and can kill malignant target cells
(32). However, the function of this cytokine in normal tissues
is still not clear. Recently, a study using mice deficient in
TRAIL found an essential role for TRAIL in thymocyte apo-
ptosis and inhibition of autoimmunity (18). Our results show
that functional FasL and TRAIL are expressed on normal IEC
during immune responses, suggesting a possible cooperation of
these ligands in peripheral lymphocyte deletion. Our data are
in line with recent publications demonstrating cross-activation
of different death systems, enabling autoamplification of apo-
ptosis following ligation of FasL, TRAIL, and TNF (11). Fol-
lowing the same concept, Lee et al. recently reported the
expression of a functional TRAIL protein in an immune-priv-
ileged site, the anterior chamber of the eye (21). In addition,
the pattern of expression of TRAIL in the eye is remarkably
similar to that of FasL, suggesting a possible cooperation be-
tween these different ligands in the elimination of activated T
cells, thereby limiting the damage to the tissues into which the
T cells infiltrate.
While the idea that T-cell-induced nonlymphoid expression
of molecules such as FasL, TRAIL, and TNF contributes to
peripheral deletion is attractive, a possible problem concerns
the effect of cyclosporine in these systems. Egr is inhibited by
cyclosporine (29), and this accounts in part for the inhibition of
FasL expression in activated T cells treated with cyclosporine
(4). In contrast, peripheral deletion is not inhibited by cyclo-
sporine (2). At present, we envision at least two possibilities.
First, it is possible that Egr in IEC and other nonlymphoid cells
is not inhibitable by cyclosporine. Alternatively, some nonlym-
phoid cells may express FasL (and other related molecules)
that is not dependent on Egr. For example, constitutive ex-
pression of FasL in the testes is not inhibited by cyclosporine
(19).
Studies with the FasL promoter have established the pres-
ence of several sites important in its transcription, such as
binding sites for NF-"B (14, 26, 27), NFAT (19, 20), activating
protein 1 (AP-1) (28), and Egr-2 and -3 (29, 30), although the
relative functional importance of these sites might differ
among species. We found that injection of the superantigen
SEB into wild-type mice or of OVA into OT-2 mice induced
Egr-1, Egr-2, and Egr-3 expression in IEC and that this was not
observed with mice deficient in TNF expression. Egr-2 and
Egr-3 have recently emerged as important transcription factors
for FasL expression in lymphoid and nonlymphoid cells (29,
30). Because induction of both Egr-2 and Egr-3 was shown to
be cyclosporine sensitive in T cells (29), the expression of the
Egr-2 and -3 genes might be dependent on NFAT. In fact, a
transcriptionally active NFAT site was identified in the Egr-3
promoter, confirming this hypothesis (24). In addition, it was
recently shown that NFAT-mediated induction of Egr-2 and/or
Egr-3 is essential for optimal FasL synthesis in vivo (38). We
have provided evidence that mutation within distal Egr- or
NFAT-overlapping sites completely abolished the transcrip-
tional activity of the bp '300 construct in primary IEC and
Egr3-HT29 cells, demonstrating that mutation in the NFAT
site affects Egr-3-induced FasL expression. However, this ob-
FIG. 10. Model of nonlymphoid ligand induction in response to the
presence of activated lymphocytes. Activated lymphocytes produce
TNF that binds its receptor, TNFR1, constitutively expressed on the
surfaces of IEC (35). TNFR1 activation induces several transcription
factors, such as Egr and NF-"B, that in turn induce TNF, FasL, and
TRAIL expression in IEC. IEC expressing functional FasL and TRAIL
then induce apoptosis of infiltrating Fas- and TRAIL-R-bearing lym-
phocytes.
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servation does not exclude a possible interaction between Egr
and endogenous NFAT. We also demonstrated that Egr-3 has
no effect on a second putative Egr-binding site using the bp
'240 construct in primary IEC and Egr3-HT29 cells, suggest-
ing that Egr-2 may act exclusively at this site. In primary IEC,
Egr-2 drove reporter expression of constructs containing either
the distal Egr- or NFAT-overlapping site or the proximal Egr-
binding site of the human FasL promoter.
We also found that overexpression of Egr-2 and Egr-3 in
IEC was sufficient to induce expression of FasL, TRAIL, and to
a lesser extent TNF mRNA. This role for Egr members in
death ligand expression is relevant, because expression of the
Egr corepressor Nab1 inhibited TNF-induced expression of
these ligands in IEC. Therefore, the Egr transcription factor
family is likely to be involved in the transcriptional regulation
of several members of the TNF ligand family in IEC.
We have also recently reported that expression of FasL by
TNF is dependent on NF-"B, one component of the TNFR
signaling pathway (35). These results are not contradictory
since mutations within both the Egr- and the "B1-binding sites
silence the murine FasL promoter (28). Taken together, these
results confirm that NF-"B and Egr-2 and -3 are important
transcription factors for the expression of murine FasL.
Sequences proximal to bp '182 on the TNF promoter con-
tain motifs for several transcription factors, including AP-1,
Egr-1, NF-"B, and SP1. For example, lipopolysaccharide acti-
vation of macrophages induces the binding of c-Jun, Egr-1, and
NF-"B to binding sites within the proximal bp '182 region of
the TNF promoter (45). We also observed an Egr-2- and -3-
dependent induction of endogenous TNF in A1.1 T cells
(N. M. Droin and D. R. Green, data not shown), suggesting a
redundancy between the different members of this family.
Studies with the TRAIL promoter have recently established
the importance of several NF-"B binding sites for TRAIL tran-
scription in T cells (1). Sequence analysis of the TRAIL pro-
moter also revealed several potential NFAT and AP-1 sites
and one potential Egr site (N. M. Droin and D. R. Green, data
not shown), suggesting that the involvement of the Egr family
members in TRAIL regulation may be direct. Thus, regulation
of TRAIL may parallel in many respects that of FasL and TNF.
Further functional studies of cooperative interactions between
transcription factors (Egr members and NF-"B) bound to
these different regulatory elements will be essential to our
understanding of the transcriptional regulation of the FasL,
TRAIL, and TNF genes in epithelia after activation of periph-
eral lymphocytes.
Taken together, these data suggest a model of ligand tran-
scriptional regulation converging on the recruitment of com-
plexes composed by shared components such as the Egr mem-
bers and NF-"B. This hypothesis suggests a very subtle
regulation of these common complexes by different combina-
tions of transcription factors in the context of different en-
hancer sequences. We must now determine which transcription
factors are required physiologically for expression of each li-
gand in nonlymphoid tissues and activated T cells. Such studies
will shed light on the specificity of these complexes and help us
to understand the expression of FasL, TRAIL, and TNF in
different cell types during immune responses.
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